Sriram Krishnaswami

8.2k total citations · 6 hit papers
59 papers, 6.1k citations indexed

About

Sriram Krishnaswami is a scholar working on Rheumatology, Hematology and Oncology. According to data from OpenAlex, Sriram Krishnaswami has authored 59 papers receiving a total of 6.1k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Rheumatology, 19 papers in Hematology and 11 papers in Oncology. Recurrent topics in Sriram Krishnaswami's work include Rheumatoid Arthritis Research and Therapies (33 papers), Autoimmune and Inflammatory Disorders Research (18 papers) and Chronic Lymphocytic Leukemia Research (9 papers). Sriram Krishnaswami is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (33 papers), Autoimmune and Inflammatory Disorders Research (18 papers) and Chronic Lymphocytic Leukemia Research (9 papers). Sriram Krishnaswami collaborates with scholars based in United States, Germany and South Korea. Sriram Krishnaswami's co-authors include Samuel H. Zwillich, David Gruben, Gene V. Wallenstein, Bethanie Wilkinson, John Bradley, Roy Fleischmann, Tamás Koncz, Joel M. Kremer, Eun Bong Lee and Richard J. Riese and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Sriram Krishnaswami

59 papers receiving 5.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

2012 739 citations Ronald van Vollenhoven, Roy Fleischmann et al. New England Journal of Medicine profile →
Tofacitinib versus Methotrexate in Rheumatoid Arthritis

2014 598 citations Eun Bong Lee, Roy Fleischmann et al. New England Journal of Medicine profile →
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

2013 548 citations Cristiano A. F. Zerbini, Birgitta Benda et al. profile →
Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study

2013 456 citations Désirée van der Heijde, Yoshiya Tanaka et al. Arthritis & Rheumatism profile →
Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis

2013 366 citations Joel M. Kremer, Zhanguo Li et al. Annals of Internal Medicine profile →
The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis.

2016 305 citations Sriram Krishnaswami, Martin E. Dowty et al. PubMed profile →

Peers

Countries citing papers authored by Sriram Krishnaswami

Since Specialization

Citations

This map shows the geographic impact of Sriram Krishnaswami's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sriram Krishnaswami with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sriram Krishnaswami more than expected).

Fields of papers citing papers by Sriram Krishnaswami

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sriram Krishnaswami. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sriram Krishnaswami. The network helps show where Sriram Krishnaswami may publish in the future.

Co-authorship network of co-authors of Sriram Krishnaswami

This figure shows the co-authorship network connecting the top 25 collaborators of Sriram Krishnaswami. A scholar is included among the top collaborators of Sriram Krishnaswami based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sriram Krishnaswami. Sriram Krishnaswami is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study 2017 ·Pediatric Rheumatology ·Nicolino Ruperto, (unknown), Hermine I. Brunner, Zbigniew Żuber, Nikolay Tzaribachev, D. Kingsbury, Ivan Foeldvari, Gerd Horneff, Elżbieta Smolewska, Richard K. Vehe, Anasuya Hazra, Rong Wang, Charles A. Mebus, Christine Alvey, Manisha Lamba, Sriram Krishnaswami, Thomas Stock, Min Wang, (unknown), Alberto Martini, Daniel J. Lovell	63
2	Predicting the probability of successful efficacy of a dissociated agonist of the glucocorticoid receptor from dose–response analysis 2016 ·Journal of Pharmacokinetics and Pharmacodynamics ·Daniela J. Conrado, Sriram Krishnaswami, Satoshi Shoji, Sheela Kolluri, Judith Hey‐Hadavi, Dorothy McCabe, Ricardo Rojo, (unknown)	17
3	Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials 2015 ·Arthritis Research & Therapy ·Vibeke Strand, Sima Ahadieh, (unknown), Jamie Geier, Sriram Krishnaswami, Sujatha Menon, (unknown), Thomas G. Tensfeldt, Elaine Hoffman, Richard J. Riese, M. Boy, Juan J. Gómez‐Reino	167
4	Safety, tolerability, and pharmacokinetics of single oral doses of tofacitinib, a Janus kinase inhibitor, in healthy volunteers 2014 ·Clinical Pharmacology in Drug Development ·Sriram Krishnaswami, M. Boy, Vincent Chow, Gary Chan	35
5	Tofacitinib versus Methotrexate in Rheumatoid Arthritis breakdown → 2014 ·New England Journal of Medicine ·Eun Bong Lee, Roy Fleischmann, Stephen Hall, Bethanie Wilkinson, John Bradley, David Gruben, Tamás Koncz, Sriram Krishnaswami, Gene V. Wallenstein, Chuanbo Zang, Samuel H. Zwillich, Ronald van Vollenhoven	598
6	Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis 2013 ·Annals of Internal Medicine ·Joel Kremer, Zhanguo Li, Stephen Hall, Roy Fleischmann, Mark C. Genovese, E. Martín‐Mola, John D. Isaacs, David Gruben, Gene V. Wallenstein, Sriram Krishnaswami, Samuel H. Zwillich, Tamás Koncz, Richard J. Riese, John Bradley	5
7	Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study breakdown → 2013 ·Arthritis & Rheumatism ·Désirée van der Heijde, Yoshiya Tanaka, Roy Fleischmann, Edward Keystone, Joel M. Kremer, Cristiano A. F. Zerbini, Myrna Cardiel, Stanley Cohen, Peter Nash, Yeong Wook Song, Dana Tegzová, Bradley T. Wyman, David Gruben, Birgitta Benda, Gene V. Wallenstein, Sriram Krishnaswami, Samuel H. Zwillich, John Bradley, Carol A. Connell, (unknown)	456
8	Pharmacokinetics of tofacitinib, a janus kinase inhibitor, in patients with impaired renal function and end‐stage renal disease 2013 ·The Journal of Clinical Pharmacology ·Sriram Krishnaswami, Vincent Chow, M. Boy, Cunshan Wang, Gary Chan	44
9	Preclinical to Clinical Translation of Tofacitinib, a Janus Kinase Inhibitor, in Rheumatoid Arthritis 2013 ·Journal of Pharmacology and Experimental Therapeutics ·Martin E. Dowty, Michael I. Jesson, Sarbani Ghosh, (unknown), Debra M. Meyer, Sriram Krishnaswami, Nandini Kishore	88
10	Lack of effect of tofacitinib (CP‐690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation ofin vitrodata 2012 ·British Journal of Clinical Pharmacology ·Pankaj Gupta, Christine Alvey, Rong Wang, Martin E. Dowty, Odette A. Fahmi, Robert L. Walsky, Richard J. Riese, Sriram Krishnaswami	32
11	Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis breakdown → 2012 ·New England Journal of Medicine ·Ronald van Vollenhoven, Roy Fleischmann, Stanley Cohen, Eun Bong Lee, (unknown), (unknown), Šárka Forejtová, Samuel H. Zwillich, David Gruben, Tamás Koncz, Gene V. Wallenstein, Sriram Krishnaswami, John Bradley, Bethanie Wilkinson	739
12	Phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease‐modifying antirheumatic drugs 2011 ·Arthritis & Rheumatism ·Roy Fleischmann, Maurizio Cutolo, Mark C. Genovese, Eun Bong Lee, Keith S. Kanik, Seth Sadis, Carol A. Connell, David Gruben, Sriram Krishnaswami, Gene V. Wallenstein, Bethanie Wilkinson, Samuel H. Zwillich	315
13	Dosing Celecoxib in Pediatric Patients With Juvenile Rheumatoid Arthritis 2011 ·The Journal of Clinical Pharmacology ·Sriram Krishnaswami, Matt Hutmacher, Jeffery Robbins, Akintunde Bello, Christine R. West, Bradley J. Bloom	10
14	Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes 2010 ·Best Practice & Research Clinical Rheumatology ·Richard J. Riese, Sriram Krishnaswami, Joel M. Kremer	86
15	A Prospective Study Comparing Celecoxib with Naproxen in Children with Juvenile Rheumatoid Arthritis 2008 ·The Journal of Rheumatology ·Ivan Foeldvari, Ilona S. Szer, Lawrence Zemel, Daniel J. Lovell, Edward H. Giannini, Jeffery Robbins, Christine R. West, (unknown), Sriram Krishnaswami, Bradley J. Bloom	42
16	Exposure-response modeling using latent variables for the efficacy of a JAK3 inhibitor administered to rheumatoid arthritis patients 2007 ·Journal of Pharmacokinetics and Pharmacodynamics ·Matthew M. Hutmacher, Sriram Krishnaswami, Kenneth G. Kowalski	50
17	Model-Based Covariate Pharmacokinetic Analysis and Lack of Cortisol Suppression by the New Inhaled Corticosteroid Ciclesonide Using a Novel Cortisol Release Model 2005 ·American Journal of Therapeutics ·Shashank Rohatagi, Sriram Krishnaswami, Marc Pfister, Srikumar Sahasranaman	34
18	An interactive algorithm for the assessment of cumulative cortisol suppression during inhaled corticosteroid therapy 2000 ·PubMed ·Sriram Krishnaswami, Günther Hochhaus, Hartmut Derendorf	16
19	A sensitive LC–MS/MS method for the quantification of fluticasone propionate in human plasma 2000 ·Journal of Pharmaceutical and Biomedical Analysis ·Sriram Krishnaswami, (unknown), Hartmut Derendorf, Günther Hochhaus	31
20	Enhanced transgene expression in rat brain cell cultures with a disulfide-containing cationic lipid 1999 ·Neuroscience Letters ·(unknown), Fuxing Tang, Sriram Krishnaswami, Edwin M. Meyer, Colin Sumners, Jeffrey A. Hughes	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact